Literature DB >> 3994144

Diethylcarbamazine inhibits acute and chronic hypoxic pulmonary hypertension in awake rats.

M L Morganroth, K R Stenmark, K G Morris, R C Murphy, M Mathias, J T Reeves, N F Voelkel.   

Abstract

Leukotriene inhibitors preferentially inhibit the acute pressor response to hypoxia in isolated rat lungs. If leukotrienes are important in hypoxic pulmonary vasoconstriction, then inhibition of their synthesis could prevent the development of chronic hypoxic pulmonary hypertension. We found that diethylcarbamazine (DEC), a leukotriene synthesis blocker, reversibly inhibited acute hypoxic pulmonary vasoconstriction in the awake rat. Rats exposed to chronic hypobaric hypoxia showed pulmonary hypertension and the production of a slow-reacting substance compared with low altitude control rats. The higher of 2 doses of DEC blocked the pulmonary hypertension and the production of slow-reacting substance in all of the hypoxic rats treated. The lower dose of DEC attenuated the pulmonary hypertension in only some of the rats. Changes in weight gain, hematocrit, or generation of prostacyclin did not explain the prevention of the pulmonary hypertension by DEC. We conclude that diethylcarbamazine inhibits acute and chronic pulmonary hypertension in the intact rat.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3994144     DOI: 10.1164/arrd.1985.131.4.488

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

Review 1.  Pulmonary diseases other than asthma as potential targets for antileukotriene therapy.

Authors:  M Peters-Golden
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in hypoxia-induced pulmonary hypertension.

Authors:  Daling Zhu; Yajuan Ran
Journal:  J Physiol Sci       Date:  2012-02-14       Impact factor: 2.781

3.  Antagonism of leukotriene receptors and administration of a 5-lipoxygenase inhibitor do not affect hypoxic vasoconstriction.

Authors:  H M Thomas; M S Sourour; D Lopez; S H Foster
Journal:  Lung       Date:  1989       Impact factor: 2.584

4.  [The role of lipoxygenase and cyclooxygenase metabolites in acute hypoxic pulmonary vasoconstriction in piglets].

Authors:  A P Zou; G Cheng; Y Q Pi; W H Wang; S B Yu; D X Wang
Journal:  J Tongji Med Univ       Date:  1989

5.  Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.

Authors:  N F Voelkel; R M Tuder; K Wade; M Höper; R A Lepley; J L Goulet; B H Koller; F Fitzpatrick
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

6.  Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.

Authors:  Laura E Fredenburgh; Jun Ma; Mark A Perrella
Journal:  Trends Cardiovasc Med       Date:  2009-02       Impact factor: 6.677

7.  Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery. Alterations after prolonged hypoxia in the rat.

Authors:  P W Shaul; B Kinane; M A Farrar; L M Buja; R R Magness
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

8.  Chronic hypoxia promotes pulmonary artery endothelial cell proliferation through H2O2-induced 5-lipoxygenase.

Authors:  Kristi M Porter; Bum-Yong Kang; Sherry E Adesina; Tamara C Murphy; C Michael Hart; Roy L Sutliff
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

9.  Increased eicosanoid levels in the Sugen/chronic hypoxia model of severe pulmonary hypertension.

Authors:  Aysar Al-Husseini; Dayanjan S Wijesinghe; Laszlo Farkas; Donatas Kraskauskas; Jennifer I Drake; Ben Van Tassel; Antonio Abbate; Charles E Chalfant; Norbert F Voelkel
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

10.  A new treatment for severe pulmonary arterial hypertension based on an old idea: inhibition of 5-lipoxygenase.

Authors:  Norbert F Voelkel; Marc Peters-Golden
Journal:  Pulm Circ       Date:  2020-03-26       Impact factor: 3.017

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.